Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

A Double‐Blind, Placebo‐Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol Dependence

Mason, Barbara J., Ritvo, Eva C., Morgan, Robert O., Salvato, Femando R., Goldberg, Gloria, Welch, Bruce, Mantero‐Atienza, Emilio·1994·Alcoholism: Clinical and Experimental Research

Abstract

A dozen studies have been published showing that opiate antagonists suppress alcohol drinking in animals, and two independent placebo‐controlled, double‐blind clinical trials of naltrexone found this agent was associated with decreased alcohol craving and consumption in alcohol‐dependent patients. Nalmefene is a newer opiate antagonist that has a number of potential advantages over naltrex‐one in the treatment of alcoholism, including no dose‐dependent association with liver toxicity and more effective binding to central opiate receptors. Consequently, a double‐blind pilot study was conducted to gather preliminary data on the safety and efficacy of nalmefene for reducing alcohol consumption in alcohol‐dependent subjects. Twenty‐one alcohol‐dependent subjects meeting admission criteria were randomly assigned to 12 weeks of double‐blind treatment with 40 mg nalmefene, 10 mg nalmefene, or placebo, resulting in 7 patients/treatment group. Nalmefene was well tolerated, with no serious adverse drug reactions. The 40 mg group had a significantly lower rate of relapse (p 0.05), and a greater increase in the number of abstinent days/week (p 0.09), than the other treatment groups. A significant decrease in the number of drinks/drinking day was noted for both nalmefene groups (p 0.04), but not for placebo. These results were supported by parallel decreases in ALT. These pilot data provide preliminary support for the hypotheses that nalmefene can be safely given to alcoholics, and that nalmefene may have a role in reducing alcohol consumption and preventing relapse, particularly at the 40 mg level. A full‐scale study is underway to confirm these preliminary findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1530-0277.1994.tb00098.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 248

Metadata

Authors
Mason, B. J., Ritvo, E. C., Morgan, R. O., Salvato, F. R., Goldberg, G., Welch, B., & Mantero‐Atienza, E.
Venue
Alcoholism: Clinical and Experimental Research
Publisher
Wiley
Published
1994-10
Volume
18
Issue
5
Pages
1162-1167
ISSN
  • 0145-6008 (ISSN-L)
  • 1530-0277
OpenAlex
W2050538748
Cited by
248
References
4
FWCI
10.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Double‐Blind, Placebo‐Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol Dependence. https://app.cochat.ai/papers/10.1111/j.1530-0277.1994.tb00098.x
The paper
Mason, B. J., Ritvo, E. C., Morgan, R. O., Salvato, F. R., Goldberg, G., Welch, B., & Mantero‐Atienza, E. (1994). A Double‐Blind, Placebo‐Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol Dependence. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.1994.tb00098.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.